in addition to augmentation therapy using human plasma-derived, purified α1-antitrypsin to supplement the low levels of active α1-antitrypsin. New therapies that target the misfolding of mutant forms of α1-antitrypsin or attempt to correct the underlying genetic mutation are being developed.
In this Primer, we summarize the epidemiology of A1ATD, discuss the pathophysiology of A1ATD-associated lung and liver complications and review current research in this field. We also consider existing treatment options for A1ATD and future developments that might further improve the outlook for patients with A1ATD.
Epidemiology
A1ATD is a relatively common disorder 2, 3 . Although most prevalent in Europe (including Scandinavia, Spain and Portugal) and North America, A1ATD occurs worldwide. A1ATD has been reported in virtually all racial subgroups studied in almost 70 countries in 11 geographical regions around the world 4 . The global number of individuals with the PI*MS or PI*MZ geno type is 116 million and those with the PI*ZZ, PI*SZ or PI*SS genotype is 3.4 million. The prevalence of A1ATD has been estimated using two detection strategies: population-based screening and case reports (also called targeted detection). Many population-based screening studies for A1ATD have been performed 4 , the largest two were performed in newborn infants in Sweden and Oregon and estimated a prevalence of PI*ZZ of 1 per 1,639 individuals in Sweden (n = 200,000) and 1 per 5,097 individuals in Oregon (n = 107,038) 5 . Data from one study indicate that approximately 100,000 individuals in the United States have A1ATD characterized by severely decreased serum levels of α1-antitrypsin 6 . Some targeted detection studies have assessed the prevalence of A1ATD in individ uals with several diseases. For example, one study estimated the prevalence of severe A1ATD in individuals with COPD as between 0% and 12%, with a mean value of 3.6%. In general, all data regarding the prevalence of A1ATD is probably confounded by the method of ascertainment and by general under-recognition of A1ATD (see Diagnosis, screening and prevention).
Genetic and environmental risk factors
A genome-wide association study tightly linked circulating α1-antitrypsin levels in a general population sample to the SERPINA1 gene cluster 7 . The detrimental role of the exposure to cigarette smoke on the clin ical phenotype of A1ATD has also been demonstrated 8 . In a Swedish study, all 35-year-old individuals with the PI*ZZ genotype had normal liver and lung function, but smoking frequency was significantly lower among patients with A1ATD than controls 9 . Never smokers with A1ATD also had abnormal chest X-rays and lung function 10 . Nevertheless, the wide range of clini cal pheno types that are associated with A1ATD could be caused by interactions between genetic and environmental factors other than SERPINA1 and smoking alone. Indeed, single studies have identified potential genetic modifiers of COPD phenotypes in patients with severe A1ATD. For example, genetic variations in MMP1 (which encodes matrix metalloproteinase 1) or MMP3 and TNF (which encodes tumour necrosis factor) have been associ ated with air transfer and chronic bronchitis, respectively, in patients with A1ATD 11, 12 , and polymorphisms in IL10, CHRNA3 and IREB2 are associated with lung function in individuals with the PI*ZZ genotype 13, 14 . The expression of the lung disease for example, ranges from asymptomatic to severe emphysema in individuals with the PI*ZZ genotype. This heterogeneity is probably the result of genetic predis position to lung disease and some environ mental factors. For example, the interplay between cigarette smoke-induced oxidative stress and Z-type α1-antitrypsin polymer ization can affect cellular inflam mation and cytokine expression 15 . Regarding the role of the environment on A1ATD, few data are available indicating that outdoor air pollution can worsen respiratory status and predict lung function decline in individuals with the PI*ZZ geno type 16, 17 . Another study revealed a significant interaction (P < 0.0001) between the PI*MZ genotype and high levels of exposure to vapours, gases, dusts and fumes on annual change in forced expiratory flow 25-75% (FEF25-75%) levels 18 . A separate study noted a significant interaction (P = 0.03) between high-level vapours, gases, dusts and fumes and annual changes in the forced expir atory volume in 1 second/forced vital capacity (FEV1/FVC) ratio 17 . Overall, larger annual declines in lung function in PI*MZ carriers, compared to individuals with the PI*MM geno type, were associated with outdoor particulate matter of ≤10 μm, and a FEF25-75% decline associated with vapours, gases, dust and fumes was observed only in never smokers with the PI*MZ genotype 18 . Unlike smoking 19 , environmental or passive tobacco smoke exposure is not a risk factor for individuals with the PI*MZ genotype 18 .
Mechanisms/pathophysiology
Misfolding and accumulation of mutant forms of α1 -antitrypsin within the ER of α1-antitrypsin-producing cells can lead to toxicity; this primarily affects the liver and to a lesser extent the lungs. The accumulation of misfolded α1-antitrypsin causes cellular damage through two main mechanisms: the perturbation of homeostasis within the lumen of the ER and the assembly of polymers (especially of Z-type α1-antitrypsin) in the circulation, in the lumen of the lung or within tissues that can cause chemotaxis and/or activation of inflammatory cells 20 . Retention of mutant α1-antitrypsin in α1-antitrypsinproducing cells leads to low or undetectable levels of α1-antitrypsin, which can cause defects in other tissues owing to a lack of proteinase inhibition, especially in the lungs.
Genetic basis of disease α1-Antitrypsin is encoded by SERPINA1 (FIG. 2) . Different α1-antitrypsin transcripts are generated in differ ent tissues owing to different transcription start sites, alternative splicing of untranslated exons [21] [22] [23] and tissue-specific pro-inflammatory cytokines, in particular, the IL-6 class of cytokines, such as leukaemia inhibitory factor and the acute-phase mediator oncostatin M [24] [25] [26] [27] [28] . A specific quantitative reverse-transcriptase PCR test has been developed to quantify the expression of the different SERPINA1 transcripts to improve understanding of the regulatory mechanisms that control SERPINA1 expression 29 . SERPINA1 is highly polymorphic and mutations in this gene cause a hereditary co-dominant autosomal disorder. Pathological SERPINA1 variants are classified as either 'deficient' or 'null' . Deficient variants occur as a result of a point mutation that causes retention of the α1-antitrypsin protein in hepatocytes and other α1-antitrypsin-producing cells, resulting in low levels of α1-antitrypsin in plasma. Null mutations generally occur owing to the presence of a premature stop codon and patients with these mutations have no detectable α1-antitrypsin in serum. The most common severely deficient variant is Z-type α1-antitrypsin and is caused by a single-nucleotide polymorphism in SERPINA1 that results in the substitution of glutamic acid for lysine at residue 342 (Glu342Lys; rs28929474), which is found at a frequency between 2% and 5% in Caucasian individuals of European descent. At least 40 other deficient variants have been identified over the past few decades; these variants are rare, the molecular mechanism by which they cause disease varies and they can be prognostic for either liver or lung diseases 30, 31 . Similarly, up to 34 null alleles have been characterized to date 32 , most of which are extremely rare.
Mutant α1-antitrypsin
The protease neutrophil elastase is the primary target for α1-antitrypsin, but it can also inhibit other proteases. α1-Antitrypsin uses the characteristic serpin inhibitory mechanism to irreversibly inhibit the activity of neutrophil elastase 33 . Z-type α1-antitrypsin is retained within the ER of hepato cytes as ordered polymers that become seques tered in inclusions, which are periodic acid-Schiff-positive, diastase-resistant on histological examin ation 34, 35 . This same process underlies the severe α1-antitrypsin plasma deficiency and intrahepatic inclu sions of other protein variants of α1-antitrypsin: Siiyama (Ser53Phe) 36 , Mmalton (ΔPhe52) 37 and King's (His334Asp) 35 . Polymerization of α1-antitrypsin also underlies the deficiency of the mild S allele (Glu264Val), I allele (Arg39Cys), Queen's allele (Lys154Asn) and Baghdad allele (Ala336Pro) 38 . However, the rate of polymer formation, which is proportional to the destabilizing effect of the mutation on the protein 39 , is much slower for the I allele, S allele, Queen's allele and Baghdad allele and explains the absence of liver disease and the association with only mild plasma deficiency.
The initial description of the polymers of Z-type α1-antitrypsin described a linkage between the reactive centre loop and the β-sheet A on adjacent Z-type α1-antitrypsin proteins 34 (FIG. 3a) . Alternative linkages of α1-antitrypsin polymerization have been described in the crystal structures of a dimer of antithrombin (linkage by a β-hairpin of the reactive centre loop and Nature Reviews | Disease Primers 181, 182 . The levels of serum aminotransferases and bilirubin (markers for liver dysfunction) are raised in 70% and 11% of infants, respectively, in their first year of life, but then levels typically decrease. Raised levels of aminotransferases remain abnormal in 15% of patients by 12 years of age and serum bilirubin levels fall to within the normal range by 6 months of age. Infants with the PI*ZZ genotype can present with jaundice, the clinical symptoms of which typically resolve by the second year of life but can progress to cirrhosis in 15% of children who had jaundice at birth 5, 183 . Some adults with the PI*ZZ genotype have slowly progressive hepatic damage that is asymptomatic and is only apparent as a minor degree of portal fibrosis. α1-Antitrypsin deficiency (A1ATD)-associated cirrhosis and hepatitis can present at any age, as can liver failure. Approximately 13% of patients with the PI*ZZ genotype die from liver disease 10 . Severe lung dysfunction associated with A1ATD, such as emphysema, develops between the third and fourth decade of life. Emphysema associated with Z-type A1ATD is typically panlobular and affects the bases of the lungs. Patients initially present with breathlessness and cor pulmonale (enlargement of the right side of the heart due to lung disease) and polycythaemia (increased numbers of red blood cells in the blood) can occur late in the disease 99 . Bronchiectasis generally presents in adults with the PI*ZZ genotype, but can be found in some children and young adults. The PI*ZZ genotype is also associated with an increased prevalence of asthma 184 , panniculitis 185 and granulomatosis with polyangiitis 186 . The underlying disease mechanisms are currently unknown, but pro-inflammatory polymers of Z-type α1-antitrypsin and deficiency of M-type α1-antitrypsin might contribute to both granulomatosis with polyangiitis and panniculitis. strand 5A 40 ; FIG. 3b) and a trimer of α1-antitrypsin (linkage by strands 1C, 4B and 5B; FIG. 3c) 
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. The bio physical characteristics of α1-antitrypsin polymers formed by refolding following denaturation by guanidine support the β-hairpin and β-sheet A linkage 42 . Data from smallangle X-ray scattering indicate that trimers, tetramers and pentamers of Z-type α1-antitrypsin all form ring-like structures, consistent with a linkage by strands 1C, 4B and 5B 43 (FIG. 3d) . In patients with A1ATD, ring-shaped polymers of α1-antitrypsin are rarely seen in inclusions from the livers of individuals with the PI*ZZ genotype 34 .
Loss of anti-neutrophil elastase activity
Mutation in SERPINA1 results in enhanced neutrophil elastase activity, which causes many effects that can contrib ute to the pathophysiology of A1ATD-associated lung disease. Enhanced neutrophil elastase activity has a range of consequences that lead to inflammation and an enhanced rate of neutrophil reactive oxygen species production (FIG. 4) . Excessive cleavage of molecules involved in the immune response (for example, complement factors, immunoglobulins, antimicrobial peptides 44 and cell surface receptors, such as the monocyte differentiation antigen CD14 (REF. 45 ) and CXC-chemokine receptor 1 (CXCR1) 46 ) results in a decreased activation of monocytes (owing to reduced responsiveness to lipo polysaccharide (LPS)) and a decreased efficiency of phagocytosis by neutro phils -one of the hallmarks of acute inflam mation. Reduced expression of low-affinity immuno globulin-γ Fc region receptor IIIB on the neutro phil surface and increased chemotaxis of neutro phils in response to IL-8 and soluble immune complexes 47 , together with degranulation of secondary and tertiary granules, further exaggerates the production of reactive oxygen species 48 . Increased cleavage of coagulation factors and ECM or connective tissue molecules (such as elastin 49 , collagen 50 , fibronectin 51 and proteo glycans 52 ) can also contribute to the pathology. Interestingly, neutro phil elastase can also induce gene expression of ECM modu lators (such as MMPs and cathepsins) by activation of disintegrin and metalloproteinase domain-containing protein 17 (ADAM17) and meprin A-mediated epidermal growth factor receptor signalling [53] [54] [55] [56] . Inactivation of metalloproteinase inhibitors (also known as tissue inhibitors of metalloproteases) 57 , secretory leuko protease inhibitor (SLPI; also known as antileukoproteinase) 44 , elafin 58 and cystatin C 59 has also been reported. Other outcomes that occur either directly or indirectly owing to decreased levels of α1-antitrypsin in the lungs include goblet cell (mucus-secreting cells) hyperplasia, increased mucus secretion and impaired muco ciliary clearance leading to defective bacterial clearance 60 . Moreover, reduced inhibition of caspase 3 can promote apoptosis of lung endothelial cells 61 . Emerging data have also indicated that leukotriene B 4 production and leukotriene B 4 receptor 1 (BLT1; also known as LTB4R1) membrane receptor expression 62 are increased in neutrophils, as is TNF-mediated peripheral blood neutrophil apoptosis 63 . Other evidence has demonstrated increased phosphorylation of the p38 mitogen-activated protein kinases and nuclear factor-κB (NF-κB) inhibitor-α and induction of MMPs and cytokines via serine/threonine protein phosphatase 2A 64 .
Accumulation of α1-antitrypsin in the ER Intracellular disposal mechanisms for misfolded α1-antitrypsin. The retention of some protein variants, such as Z-type α1-antitrypsin in hepatocytes, is the inciting event in the pathophysiology of A1ATD-associated liver disease 65 (FIG. 5) and leads to apoptosis and oxidative stress of hepatocytes. In healthy cells, misfolded proteins that have accumulated in the ER are degraded by the ubiquitin-proteasome system -a process called ER-associated protein degradation (ERAD) -or by macro autophagy. In A1ATD, the increased load of misfolded proteins in the ER causes excessive activation of these cellular disposal mechanisms. Soluble Z-type α1-antitrypsin is monitored in the ER and diverted to the ERAD pathway, whereas Z-type α1-antitrypsin polymers are degraded by macroautophagy. Much of the work investigating the handling of misfolded α1-anti trypsin has concentrated on the Null Hong Kong (NHK) variant of α1-antitrypsin. The ERAD pathway is the main pathway for degradation of NHK α1-antitrypsin owing to its inability to fold 66 , but even polymerogenic mutants of α1-antitrypsin are targeted for degradation by the ERAD pathway, despite having near-native conformations 66, 67 . The Z variant of α1-antitrypsin folds more slowly than the M variant of α1-antitrypsin and can adopt an intermediate conformation; both of these factors might contrib ute to the targeting of Z-type α1-antitrypsin to the ERAD pathway 35, 68, 69 . Glycoproteins (such as α1-antitrypsin) undergo cycles of N-glycan modification while within the ER. This mechanism acts as a timer to identify proteins that fail to fold in an appropriate time. Abnormalities in the enzymes involved in this process might have a role in α1-antitrypsin misfolding in A1ATD. Experimental overexpression of ER mannosyl-oligosaccharide 1,2-α-mannosidase (ERManI), an enzyme that trims . The hepatocyte SERPINA1 promoter is located within exon 1C, upstream of the hepatocyte transcription start site 21, 187 . Alternative promoter regions are located upstream of exon 1A and before exon 1B; these control SERPINA1 expression in monocytes and macrophages 21, 188 . The most common α1-antitrypsin deficiency -associated mutations are depicted.
mannose residues from N-glycans, accelerates degradation of both NHK and Z-type α1-antitrypsin variants in vitro 70, 71 , whereas inhibition of ERManI stabilizes the variants 72 . Interestingly, a less-frequent allele variant of MAN1B1 (encoding ERManI) that is associated with reduced expression of ERManI has been reported more frequently than expected in children who require transplantation for Z-type A1ATD-associated liver disease, suggesting that protein glycosylation has a role in the accumulation of α1-antitrypsin in patients with A1ATD 73 . Whole organelles (for example, the ER) or large protein aggregates can be degraded by macroautophagy. This process involves engulfment of the structures by endomembranes that form autophagosomes, which fuse with the lysosome so that the contents are hydrolysed and degraded. Both in vitro and mouse models support a role for autophagy in the degradation of Z-type α1-antitrypsin 66 . Treatment of mice used to model A1ATD with carbamazepine (an autophagy-enhancing drug) reduces the accumulation of Z-type α1-antitrypsin in the liver 74, 75 . It is currently unknown whether macroautophagy shows selectivity for ER-containing polymers of α1-antitrypsin or whether the turnover of ER in general is just increased. ER stress. When misfolded proteins accumulate within the ER and threaten to precipitate, the cell is said to experi ence ER stress. ER stress triggers an unfolded protein response (UPR) that reduces the influx of nascent proteins into the ER and simultaneously reprogrammes the cell to fold or dispose of the misfolded proteins more efficiently (FIG. 6 ). This process involves the detection of ER stress by three ER stress sensors 76, 77 . The misfolding variants NHK and Saar α1-antitrypsin, which are truncated and unable to fold, can trigger the UPR if expressed even at low levels [78] [79] [80] [81] [82] [83] . All newly synthesized proteins sequester chaperones (including 78 kDa glucose-regulated protein (also known as BiP)) to keep them in a competent state for subsequent folding or direct them to the ERAD pathway if folding is impaired. NHK and Saar variants are normally efficiently degraded by the ERAD pathway, but, if allowed to accumulate, will sequester large numbers of BiP, leading to ER stress. The mechanism by which ER stress sensors are activated is debated. One model suggests that the sequestration of BiP by accumulated misfolded proteins reduces the level of free BiP, leading to the activation of ER stress sensors 84 . An alternative model suggests that the ER stress sensors interact directly with misfolded protein 85 . Nature Reviews | Disease Primers
King's Interestingly, the dramatic accumulation of polymeric α1-antitrypsin does not activate the UPR in most circumstances, despite ER stress 82, 83, [86] [87] [88] [89] [90] . As α1-antitrypsin poly mers are generally thought to be relatively well-folded structures, they might not present misfolded stretches of amino acids and so fail to activate ER stress sensors. However, the accumulation of α1-antitrypsin polymers does seem to sensitize the cell to second insults that can cause ER stress 83, [86] [87] [88] . The mechanism for this sensitization is not well understood, but might involve altered protein mobility in the ER lumen, either owing to local alterations in viscosity or to the degree of ER interconnectivity 83 . Accumulation of α1-antitrypsin polymers can affect various intracellular signalling pathways, leading to the transcriptional upregulation of pro-inflammatory genes, including increased basal and LPS-induced expression of IL6 and CXCL8 in monocytes derived from patients with Z-type A1ATD compared with individuals without A1ATD. Upregulation of pro-inflammatory genes is associ ated with intracellular accumulation of Z-type α1-antitrypsin polymers in monocytes 91 .
The accumulation of polymerogenic α1-antitrypsin triggers NF-κB signalling, which has been termed the 'ER overload response' . Little is known about this response, but leakage of calcium from the ER might have a role in NF-κB activation; chelation of cytosolic calcium has been shown to limit the activation of NF-κB 88 . By contrast, primary bronchial epithelial cells that express low levels of Z-type α1-antitrypsin without polymer formation also showed enhanced basal NF-κB signalling 89 . This indicates that increased NF-κB signalling is not restricted to activation of the ER overload response. A possible alternative mechanism might involve the increased activity of ADAM17. Primary bronchial epithelial cells that are isolated from individuals with the PI*ZZ geno type show hyperactive extracellular signal-regulated kinase signalling, which is dependent on the activity of ADAM17. Moreover, increased activity of ADAM17 has been reported on the surface of neutrophils of patients with A1ATD.
Extracellular α1-antitrypsin polymers
Polymers of α1-antitrypsin can also be detected in the blood 92 , bronchoalveolar lavage fluid and lung tissue of patients with A1ATD 93, 94 . It is unclear if most polymers are formed by the polymerization of secreted Z-type α1-antitrypsin in the extracellular space, as they can also be secreted at low levels by dying cells 95 . However, most extracellular polymers are of hepatic origin, as the circulating levels of these polymers fall to undetectable levels 4 days after liver transplantation 92 . α1-Antitrypsin can also be synthesized locally by airway epithelial cells, but at levels that are too low to allow the formation of intracellular polymers 89 . Extracellular polymers of α1-antitrypsin have proinflammatory effects. For example, they are chemotactic and stimulatory for neutrophils and probably contribute to both pulmonary inflammation and the increased incidence of vasculitis or panniculitis seen in individuals with the PI*ZZ genotype following the deposition of these polymers in other tissues 96 .
Diagnosis, screening and prevention A1ATD is a widely underdiagnosed condition. The estimate of the mean interval between the development of the first symptom of disease (usually dyspnoea (shortness of breath)) and the initial diagnosis has not changed over the past 20 years and ranges from 5.6 to 8.3 years 3, 97 . Similarly, the number of health care providers that patients with A1ATD see before the diagnosis is initially made has not lessened over time 2 . This delay in diagnosis has been associated with adverse psychosocial effects 3 and delays the implementation of disease manage ment and the identification of family members at risk of A1ATD. Thus, better recognition of this disorder by health care providers is urgently needed.
Underdiagnosis of A1ATD is supported by three lines of evidence. First, in all countries where diagnosis of A1ATD has been examined, only a small minority of the actual number of individuals with A1ATD have been diagnosed with this disorder 98 . Second, few physicians comply with the American Thoracic Society and European Respiratory Society (ATS/ERS) guidelines that Nature Reviews | Disease Primers state that all patients with COPD should be assessed for A1ATD 99 . Third, patients with A1ATD frequently experience long delays and see many health care providers between their first symptom and diagnosis of A1ATD.
Diagnostic tests
Owing to the heterogeneous clinical presentation, the diagnosis of A1ATD is predominantly based on the results of laboratory testing, although clinical features of A1ATD may be useful for selecting individuals for testing (FIG. 7) . The diagnostic tests are well established worldwide and involve the quantification of either plasma or serum α1-antitrypsin levels, typically performed using a nephelometer, in combination with either genotyping or protease inhibitor typing 100 . Genotyping usually begins with the detection of the most common disease-associated alleles (S and Z) using genotype-based allele-specific amplification by quantitative PCR. This genotyping can be performed using DNA isolated from dried blood spots, whole blood and saliva, and results from this diagnostic test dictate what subsequent diagnostic tests are performed 101 (for example, see FIG. 7 ). Reflex testing (that is, follow-up testing) for the identification of alleles other than the S allele or the Z allele is usually performed by protease inhibitor typing using isoelectric focusing of serum or plasma. Each phenotype of A1ATD exhibits a characteristic banding pattern on isoelectric focusing that can be compared to known reference samples 100 . Although the S allele and the Z allele are present in >95% of all patients with A1ATD, the remaining <5% have rare deficiency alleles, such as those associated with reduced, dysfunctional or absent plasma α1-antitrypsin levels 102 . These rare alleles are not detected by routine diagnostic methods but require a combination of protease inhibitor typing and next-generation sequencing of SERPINA1 (REF. 102 ).
Patient selection for diagnostic testing
Three approaches to select individuals for diagnosis testing of A1ATD exist. First, the diagnostic testing of individ uals with signs or symptoms consistent with A1ATD, such as early-onset, primarily lower-lobe emphysema. In the past, this paradigm led to under diagnosis and late diagnosis of A1ATD. Second, predisposition testing of those who might be at high risk for A1ATD, such as asymptomatic individuals carrying a genetic mutation in SERPINA1 and who have low levels of α1-antitrypsin and a family member with A1ATD. Development of symptoms is likely for these patients, but it is not certain. Third, targeted detection in patients with a clinical reason to suspect A1ATD, including all patients with conditions associated with increased prevalence of A1ATD, such as COPD, poorly responsive asthma, crypto genic liver disease, granulomatosis with poly angiitis, bronchi ectasis of unknown aetiology and panniculitis, in addition to first-degree relatives of patients with A1ATD. Targeted detection is similar to diagnostic testing but applies the ATS/ERS guidelines for the diagnosis and management of patients with A1ATD and has been shown to substantially increase the rates of diagnosis 103 . The use of the ATS/ERS criteria for targeted detection has been shown to enrich the detection of A1ATD; the allele frequency for the Z allele was over fourfold higher in the targeted popu lation than an unselected sample of the general population 103 . Guidelines about the potential benefits of targeted detection versus screening should be revisited, particularly in lieu of the increased understanding of the pathogenesis of A1ATD-associated disease.
Screening
Screening guidelines for A1ATD are dynamic and rapidly evolving. The ATS/ERS guidelines do not recommend population-wide neonatal screening for A1ATD 99 (that is, the testing of groups without known risk factors). This is based on evidence from a Swedish study 104 , which showed that, although neonatal screening reduced parental smoking rates following the detection of a genetic mutation in SERPINA1, there was an increased incidence of parental distress and a negative effect on the motherchild relationship 104 . In addition, the ATS/ERS guidelines do not generally recommend universal screening of adolescents <11 years of age, but suggest that screening should be discussed with individuals in areas with a high prevalence of A1ATD or if parental smoking rates are high, providing that adequate genetic counselling is given. Recommendations for adults are similar to those for adolescents 99 . The ATS/ERS guidelines 99 recommend testing high-risk groups, including all individuals who are appropriate for targeted detection. This screening approach has been shown to increase the detection of A1ATD.
The 2014 Global Initiative for COPD (GOLD) recommendations 105 quote the WHO 106 , who recommend that patients with COPD from areas with a particularly high prevalence of A1ATD should be tested for A1ATD. In addition, they noted that individuals with COPD with A1ATD present with panlobular, lower-lobe emphysema (compared to centrilobular apical distribution in COPD) at a younger age (<45 years) compared with patients with The nascent α1-antitrypsin protein is translated and enters the endoplasmic reticulum (ER) where it undergoes N-linked glycosylation. Glucose residues are trimmed from α1-antitrypsin by the action of glucosidase I (GS1) and GS2, which promotes interaction of the nascent protein with the lectin chaperones calnexin (CNX) and calreticulin (CRT). This allows the folding of the protein by ER stress protein 57 (ERp57; also known as protein disulfide-isomerase A3), following which it is deglycosylated by GS2. If folding of α1-antitrypsin is correct, it is exported from the ER and trafficked to the Golgi apparatus. By contrast, misfolded α1-antitrypsin (for example, the null Hong Kong variant (NHK) or the Z-type isoforms) is reglycosylated by uridine diphosphate (UDP)-glucose:glycoprotein glucosyltransferase 1 (UGGT1), which allows the reinteraction of misfolded α1-antitrypsin with CNX and CRT and refolding by ERp57. This cycle can persist, but misfolded α1-antitrypsin eventually undergoes demannosylation by ER α-mannosidase I (ERManI) and ER degradation-enhancing α -mannosidase-like protein (EDEM). Further demannosylation leads to the interaction of α1-antitrypsin with protein OS-9 (OS-9) and 94 kDa glucose-regulated protein (GRP94; also known as endoplasmin), and delivery to HMG-CoA reductase degradation 1 (HRD1; also known as the E3 ubiquitin-protein ligase synoviolin) complex (containing glycoprotein 78 (gp78; also known as the E3 ubiquitin-protein ligase AMFR)) for ER-associated degradation (ERAD). Misfolded α1-antitrypsin (for example, the NHK isoform) can also accumulate in the ER and is speculated to sequester binding immunoglobulin protein (BiP; also known as GRP78) away from the ER stress sensors protein kinase RNA-like ER kinase (PERK; also known as eIF2αK3), activating transcription factor 6 (ATF6) and inositol-requiring enzyme 1 (IRE1), leading to the activation of the unfolded protein response (UPR) and ER stress. By contrast, the accumulation of Z-type α1-antitrypsin results in the formation of ordered polymers that lead to the activation of the ER overload response (EOR) and upregulation of pro-inflammatory cytokines. The underlying mechanisms of polymer-mediated activation of the EOR are poorly understood, but seem to require the release of calcium from the ER lumen, nuclear factor-κB (NF-κB) signalling and a pro-inflammatory response. Under some circumstances, polymers of α1-antitrypsin can be degraded by macroautophagy.
COPD and suggest that family members at risk of A1ATD should be identified. The GOLD recommendations are not dissimilar from those that have led to substantial underdiagnosis of A1ATD for the past 50 years.
A1ATD registries
Data from rare disease patient registries increase awareness and knowledge of rare diseases, and is important for supporting both clinical and epidemiological research and monitoring of orphan drugs and the use of off-label medications 107 . Moreover, these registries are important for patients and their families; they provide a beneficial effect on health and social services planning and the ability to improve quality of care, quality of life (QOL) and patient survival. According to the European Organisation for Rare Diseases, the ideal patient registry should be diseasecentred, be able to be used in combination with other data sets, contain a minimum set of common data elements, be sustainable through the encouragement of public-private partnerships, should include data from various sources (patients and health care professionals) and should link with corresponding biobank data. Currently, no A1ATD registries exist that meets these criteria.
The first prospective registry for patients with A1ATD was the National Heart, Lung and Blood Institute (NHLBI) Registry, which enrolled 1,129 patients with severe A1ATD between 1989 and 1992 and followed them until 1996 (REF. 108 ). This registry collected information on patient demographics, medical history, measurements of pulmonary function and other laboratory evaluations at baseline and at 6-month or yearly intervals during follow-up. Data from this registry have produced some of the pivotal findings on the natural history of A1ATD, patient mortality and problems associated with a delayed diagnosis. In addition, the effects of α1-antitrypsin augmentation therapy for patients were examined, although it was recognized that these results needed to be viewed with circumspection as results were not generated from a randomized controlled trial.
The current Alpha-1 Foundation Research Registry for patients in the United States commenced enrolment in 1997 and enrolled patients with mildly deficient genotypes between 1997 and 2002 (REF. 109 ). This registry is a contact registry, allowing appropriate patients with A1ATD to receive invitations to participate in clin ical trials, although there are plans to enlarge the remit of this registry. An Alpha One International Registry was also founded in 1997, which aims to establish an inter national database of patients with A1ATD to collect data on demographics, to promote and coordinate basic and clinical research into A1ATD, to collect, assess and dissemin ate information about different aspects of A1ATD and, also, to raise support and awareness of A1ATD. The Alpha One International Registry now includes almost 20 European and non-European countries 110 . There is only one inclusion criterion for the international registry, in that the patients must have a PI*ZZ, PI*SZ or other severely deficient phenotype. Some patients (for example, patients in certain national registries) received annual follow-up to collect information to allow the document ation of disease character istics and treatments, as well as the smoking habits and lung and liver function of patients. There are also other large non-affiliated registries for A1ATD 103, 111 .
Prevention
There are compelling reasons to identify patients with A1ATD early, for example, to allow patients access to specific therapies and improve opportunities to avoid the environmental triggers of lung disease, including by the avoidance of personal and passive cigarette smoking [112] [113] [114] . Personal cigarette smoking is associated with a considerable reduction in the lifespan of patients with A1ATD 115 , and one study has shown that never smokers with A1ATD might have normal lifespans 115 . Importantly, patients with A1ATD who have developed COPD do so following exposure to a much lower number of packyears of cigarette smoking than individuals with COPD in the absence of A1ATD.
The early identification of A1ATD in neonates, adolescents and adults is associated with a reduction in the number of patients electing to start smoking, with lower addiction rates as a consequence and, also, an increase in smoking cessation rates 116, 117 . For these reasons, counselling on the avoidance or cessation of smoking should be the main focus for physicians and health care providers following the identification of patients with A1ATD of any age.
In addition to exposure to cigarette smoke, some occupational exposures, such as mineral dust and certain fumes, are associated with increased impairments in lung function and symptoms of respiratory disease in patients with A1ATD 118 . Modifiable risk factors for liver disease are less well understood, but obesity is known to increase the risk. In addition, men are more at risk of liver disease than women 
Monitoring complications of A1ATD
Monitoring lung complications. Spirometry (a lung function test), typically used in patients with A1ATD who have emphysema, results include a reduced FEV1, a reduced FEV1/FVC ratio, air trapping (raised residual volume/total lung capacity ratio) and a low diffusion capacity. A partial reversibility of the airflow obstruction (as defined by an increase of 12% or 200 ml in FEV1 after a bronchodilator) is common in individuals with COPD secondary to A1ATD. Beyond this, CT is a good parameter for lung diagnosis and has been used in various A1ATD augmentation therapy trials.
Monitoring liver complications.
Many authorities, such as the American Association for the Study of Liver Disease (AASLD), suggest regular monitoring (at least once per year) of patients with A1ATD for the development of liver disease by a physician who is familiar with liver disease and associated complications 120 . Monitoring should include history and physical examination sensitive for liver disease, such as focusing on the detection of splenomegaly, and laboratory assessment of white blood cell count, platelet count, levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, albumin and bilirubin, and assessment of the inter national normalized ratio. Progressive liver disease is often accompanied by granulo cytopaenia, thrombocyto paenia and increased levels of liver enzymes and bilirubin, and coagulopathy. As with the detection of other liver diseases, a baseline liver ultrasonography is often considered useful and is recommended in guidelines issued by the AASLD every 6 months for patients at increased risk (>2% per year) of hepatocellular carcinoma 121 . Although data for the risk of hepatocellular carcinoma in A1ATD are lacking, the AASLD guidelines should be applied to patients with A1ATD who have evidence of cirrhosis, portal hypertension or persistently large increases in liver tests.
Management
Lung disease
The 2011 GOLD strategy can identify patients with A1ATD who are at increased risk of poorer outcomes from lung disease, specifically focusing on mortality, lung function decline and exacerbations 122 . In the Swedish registry of individuals with the PI*ZZ genotype, respiratory symptoms were the most common presenting feature of A1ATD (in 43% of patients) and respiratory disease was the most common cause of death (in 55% of patients) 10 . The presence of lung disease is dependent on the smoking history of the patient; in never smokers, 28% of patients fulfilled spirometric criterion for COPD, which rose to 72% in ex-smokers.
The rationale for the treatment of A1ATD-associated lung disease is to increase the levels of α1-antitrypsin in the lung towards levels seen in healthy individuals (that is, augmentation therapy), thus reversing the lack of inhibition of neutrophil elastase and other proteases, which, when uninhibited, can cause emphysema. Initially, augmentation therapy was performed by the intravenous delivery of plasma-purified α1-antitrypsin to patients 123 , which resulted in increased levels of α1-antitrypsin and increased inhibition of neutrophil elastase both in serum and on the pulmonary epithelial surface. Data from numerous clinical trials have shown a clinical benefit of the use of augmentation therapy for the treatment of A1ATD (TABLE 1) . Augmentation therapy is usually commenced with evidence of lung disease that often equates to a decreased FEV1 and is administered once per week as intravenous infusions. Severe adverse effects of augmentation therapy are rare, but might include anaphylaxis or congestive heart failure; minor adverse effects can include chills, urticarial rashes, fatigue, nausea and vomiting 124, 125 . Concerns about the purity of human plasma-derived, purified α1-antitrypsin and the transmissibility of infection have led to the evaluation of transgenic and recombinant sources of α1-antitrypsin. Recombinant α1-antitrypsin has been successfully produced in bacteria, yeast and transgenic sheep (engineered to produce α1-antitrypsin in their milk); but, these recombinant proteins have lack of or abnormal glycosylation, which causes altered renal clearance and a short half-life follow ing intravenous administration 126 . Clinical trials investigating the use of an inhaled, recombinant form of α1-antitrypsin that has an appropriate pulmonary halflife are currently underway. In addition, aerosolization of plasma-purified α1-antitrypsin and recombinant α1-antitrypsin is effective at delivery to both the alveolar surface and the alveolar interstitium, but whether the amount of α1-antitrypsin is of sufficient quantity for clinical efficacy has not yet been evaluated 127, 128 .
Other treatments for A1ATD-associated lung disease include therapeutics that are commonly used for the management of COPD, including short-acting and long-acting β-adrenergic receptor agonists, muscarinic receptor antagonists (anticholinergics), in addition to influenza and pneumonia vaccination 99 .
Liver disease
Currently, there is no specific treatment for A1ATD-associated liver disease, and treatments for progressive liver injury are primarily supportive and focus on prevent ing malnutrition and rickets, and managing the complications of portal hypertension, such as ascites or variceal bleeding. Patients with A1ATD-associated cirrhosis can remain stable with compensated disease and minimal signs and symptoms for years 129 . In these patients, the detection of cirrhosis with portal hypertension is crucial, so the patient can be cautioned against the development of splenic injury from playing contact sports, advised to abstain from alcohol, undergo surveillance for variceal bleeding and cautioned to avoid the use of NSAIDs. Consumption of NSAIDs in patients with portal hypertension can result in life-threatening bleeding, even in well-compensated patients. There are no data regarding alcohol consumption in individuals with the PI*ZZ genotype who have no evidence of liver injury. AASLD guidelines for adults with hepatitis C virus infection without evidence of liver injury suggest that up to three alcoholic drinks per week might be safe.
For life-threatening, progressive liver failure or uncompensated cirrhosis, liver transplantation is the only therapeutic option. In the United States, patients at the highest need for a liver transplant are classified by empirically derived severity scores for both children and adults, which are correlated with an increasing risk of mortality without transplantation. The early evalu ation at a transplant centre is recommended for patients with signs or symptoms of deteriorating liver function, although in the United States neither early addition to the transplant wait list or the time spent on the list influence the severity scores. In other countries, wait lists and liver transplantation are highly variable and are often influenced by time to referral, waiting and centre-specific factors. Many transplant centres have reported excellent liver transplant outcomes for A1ATD and outcomes are often better in patients with A1ATD than those with other liver diseases; 1-year survival rates are 73% in adults and 87% in children, dropping to 60% and 83%, respectively, at 5 years 130 . In addition to cadaver-based donor transplantation, living donor liver transplants in infant (using a donated left lateral segment of the liver) and adult (using a split liver donation) patients with A1ATD are also success ful, including surgeries performed using a donor liver from an individual with the PI*MZ genotype 131 . Complications of liver transplantation include hepatic artery thrombosis, portal vein thrombosis, severe graft dysfunction, sepsis, intraoperative death, lympho proliferative disease, chronic rejection and biliary complications. Death from liver transplantation occurs primarily in the first 6 months, most often due to haemorrhage, infection or graft failure (~5-10%) 132 .
Quality of life
Life expectancy A1ATD can both shorten survival 108, 115, [133] [134] [135] [136] and can compromise the QOL of patients 137 (TABLE 2) .
A1ATD is associated with considerable morbidity and mortality 138 . The median age at death for smokers with severe A1ATD is estimated at 40 years 115 and, in a separate study, the cumulative survival up to 50 years of age was 52% 135 . In the largest available longitudinal study from the NHLBI Registry of individuals with A1ATD 108 , the mortality rate was approximately 3% per year for patients with A1ATD (in which most of the subjects were either current (8%) or ex-smokers (72%)).
FEV1 is a major correlate of mortality in A1ATD and patients entering the NHLBI Registry with an FEV1 of >50% had a normal expected survival, whereas patients with a baseline FEV1 of <15% had a 3-year mortality rate of 36% 136 . In a Danish registry of 347 patients, the median survival of patients with an FEV1 of <25% was 6.3 years, but increased for patients with an FEV1 of >25% (10.5 years) and an FEV1 of >50% (14.2 years) 133 . FEV1 (REF. 108 ) and thoracic CT densitometry 139 are both important predictors of patient survival, with a more rapid deterioration associated with the patient being a current smoker, between 30 and 44 years of age, of male sex, a predicted FEV1 between 35% and 60% and a history of asthmatic features, chronic bronchitis and episodes of pneumonia 108, 140 . COPD is less prevalent and patient survival is longer in never smokers with A1ATD. For example, the median age at death of never smokers with COPD and A1ATD has been estimated to be 65 versus 40 years for patients with COPD and A1ATD who smoked 115 . In addition, never smokers with the PI*ZZ genotype who were asymptomatic had a normal lifespan (an odds ratio for death of 0.7 compared with age-matched and gender-matched peers) 134 . Other factors that contribute to the prognosis of patients with A1ATD include the initial reason that prompted diagnosis of A1ATD, for example, the standardized mortality ratio for patients with A1ATD is highest (5) in patients who are diagnosed following the development of liver symptoms 134 .
The most frequent cause of death among patients with A1ATD is COPD or sequelae 136 , including malignancy (not hepatocellular carcinoma), diverticulitis, sepsis and/or infection and trauma. In the NHLBI Registry, emphysema accounted for 72% of deaths and cirrhosis for 10% in all patients with A1ATD 136 , whereas among never smokers with the PI*ZZ genotype, emphysema accounted for fewer deaths (45%), but liver disease accounted for more (28%) 134 .
Associated complications
A1ATD also contributes to substantial morbidity and impaired QOL. As with patients with COPD, patients with A1ATD-associated COPD experience depression (25%), clinically relevant anxiety (36%), dyspnoea and impaired health-related QOL 141 . The number of patients with anxiety and depression was similar among patients with COPD with or without A1ATD, but dyspnoea was more common in patients with A1ATD (assessed using the Modified Medical Research Council Dyspnoea Scale) and so was their health-related QOL (based on the St George's Respiratory Questionnaire). In a series of 1,062 individuals with severe A1ATD 137 , those >59 years of age experi enced fewer exacerbations and had better QOL scores (assessed using the St George's Respiratory Questionnaire and the 36-Item Short-Form Health Survey) than younger individuals.
Health-related QOL improved in patients with A1ATD who received augmentation therapy following participation in a disease management programme, which consisted of directed patient self-education (with a comprehensive reference guide describing COPD and A1ATD) and organized supervision (monthly telephone conversations with A1ATD programme coordinators and supervising participants' understanding of their long-term treatment plans) 142 . Participation in disease manage ment programmes was also associated with a 1-year improvement in medication adherence, enhanced compliance with supplemental oxygen and reductions in the use of some health care resources (although not overall hospitalization rates) 142 . However, augmentation therapy alone has not been shown to improve healthrelated QOL measures, despite slowing the progression of emphysema and exacerbations 124, 143 .
Outlook
The reasons why the clinical presentation of disease in individuals with the PI*ZZ genotype is so variable remain unclear, but this might, in part, be owing to the contributions of genetic modifiers, such as MAN1B1 (REF. 71 ). The use of induced pluripotent stem cells (iPSCs) from patients with A1ATD and severe liver disease 144, 145 , which show delayed clearance of Z-type α1-antitrypsin and have a more prominent accumulation of inclusions when differentiated into hepatocytes, combined with whole-genome analysis would allow characterization of these differences and is likely to clarify the effect of genetic modifiers and help to identify patients who are more likely to develop liver disease.
Augmentation therapy
Augmentation therapy with purified α1-antitrypsin is not universally accepted for the prevention of emphysema in patients with A1ATD, although recent trials using surrogate end points, such as CT lung density measurements, for lung protection have been encouraging 124, 143, 146 . On balance, most evidence supports the efficacy of augmentation therapy in slowing the progression of emphysema in patients with A1ATD. Augmentation therapy has some downsides: treatment is expensive and requires repeated, lifelong, intravenous infusions. Moreover, the estimate of the level of plasma α1-antitrypsin required to protect against emphysema (11 μM) is arbitrary and was based on the not fully proven hypothesis that individuals with the PI*SZ genotype who do not smoke do not have an increased risk for COPD. The optimal dose of augmentation therapy has yet to be determined, as patients receiving augmentation therapy lose some of the immunomodulatory effects of α1-antitrypsin just before they receive their next infusion. One study conducted in 2015 (the RAPID study) 124 also suggested that higher doses of α1-antitrypsin resulted in less lung density decline, observed using CT, than lower doses. In addition, the full mechanism of the protective action of augmentation therapy is currently unknown; if the effect of α1-antitrypsin is solely mediated by correction of the protease-antiprotease balance or if the beneficial effects are evident primarily due to modification of inflammation requires further research.
Emerging therapies
Many new approaches are currently being examined for their use in the treatment of A1ATD. Extensive studies have been published using in vitro analyses of the molecular structure of α1-antitrypsin and more than ten different compounds have been shown to block liver injury in the PiZ mouse model (that is, transgenic mice expressing the human Z-type α1-antitrypsin) of α1-antitrypsin liver disease, although none have been approved for human use 74, 147, 148 . SERPINA1 silencing. Therapies that target the synthesis of Z-type α1-antitrypsin, aiming to prevent the accumulation of these proteins and subsequent liver injury, are currently being examined through the application of RNA inhibition technology. Preclinical data obtained from the PiZ mouse model showed the complete reversal of the liver injury following the delivery of SERPINA1 small interfering RNAs (siRNA) 149 . Alnylam Pharmaceuticals (Cambridge, Massachusetts, USA) is undertaking a phase I trial to examine the safety of siRNA-mediated inhibition of Z-type α1-antitrypsin synthesis as a therapy for liver disease. One of the major caveats associ ated with the use of SERPINA1 siRNA is that this would prevent all α1-antitrypsin production, which could cause further lung damage. To counteract this, patients receiving α1-antitrypsin siRNA will require supplementation using, for example, transfection with the normal gene (using, for example, viral vector-mediated gene therapy) and/or augmentation therapy.
Intracellular degradation of Z-type α1-antitrypsin.
Methods to accelerate the intracellular degradation of Z-type α1-antitrypsin as a treatment for liver disease have also been assessed. Data from in vitro and mouse model experiments have shown that enhanced macroautophagy can reduce the burden of Z-type α1-antitrypsin in the liver and can also reduce liver injury 74, 147, 148 . Drugs that enhance autophagy, such as sirolimus (also known as rapamycin), carbamazepine and the bile acid 24-norursodeoxycholic acid (norUDCA), in addition to a genetic approach used to augment the expression of key autophagy regulators, have all been shown to reduce Z-type α1-antitrypsin accumulation in hepatocytes and to reduce liver cell injury in a mouse model system 74, 145 . However, excessively high doses of all of these agents were required to show an effect. A phase II trial assessing lowdose carbama zepine in patients with PI*ZZ-associated cirrhosis is currently underway, although results to date have been inconclusive 150 . Improving α1-antitrypsin folding. Other studies have focused on the use of chemical chaperone approaches to improve correct folding of α1-antitrypsin and to augment the secretion of Z-type α1-antitrypsin instead of retention in the liver (FIG. 5) . These approaches might be able to treat both the lung and the liver; however, the primary barrier to this is the large volume of α1-antitrypsin protein that is synthesized per day. If a 1/1 binding stoichiometry is needed for efficacy of these drugs, a large concentration of drug would need to be delivered to the hepatocyte ER, which might prove clini cally difficult. Nonetheless, in vitro studies have shown that several compounds promote the secretion of Z-type α1-antitrypsin and one of these compounds, 4-phenylbutyrate, was also effective in a mouse model 151 . Following on from these studies, a pilot trial was conducted in patients showing no effect on α1-antitrypsin secretion 152 . Results from this trial can probably be explained by the inability of drug levels to reach the therapeutic range in patients, as those documented in the mouse model 152 . Protein folding systems found within different cellular compartments are highly intertwined 153 and data from some studies indicate that targeting maladaptive protein folding responses in the cytosol can improve the folding of substrates in the ER, including Z-type α1-antitrypsin 154 . One study has identified the histone deacetylase 7 inhibitor suberoylanilide hydroxamic acid as a molecule that can restore the secretion of Z-type α1-antitrypsin from epithelial cells 155 .
Inhibition of α1-antitrypsin polymerization. Strategies designed in silico or using cell-free systems for the therapeutic disruption of Z-type α1-antitrypsin polymerization (probably an event separate to the protein retention signal) have also been examined 148, 156 . These largely peptide-based approaches aim to modulate the conformational behaviour of α1-antitrypsin by targeting it directly to fold correctly, stabilize functional conformers and limit the population of polymerogenic inter mediates [157] [158] [159] [160] [161] [162] [163] . However, many of these compounds had an aberrant effect following examination in vitro and there have been difficulties with creating medicinal molecules for use in animal models. Moreover, compounds that share a similar structure to the reactive centre loop of α1-antitrypsin (reactive loop analogues) can generate complexes with α1-antitrypsin that do not show antiprotease activity. Nonetheless, these molecules could still have potential for the treatment of α1-antitrypsin accumulation in hepatocytes.
M-type α1-antitrypsin synthesis. Several studies that have progressed to evaluation in clinical trials, have evaluated strategies to synthesize M-type α1-antitrypsin in tissues outside the liver, which might then lead to an increase in serum levels to protect patients from lung disease, but which would not change the risk of liver injury 164, 165 . However, to date, these studies have only been able to generate <5% of the serum M-type α1-antitrypsin level thought to be needed for a therapeutic benefit in humans using an adeno-associated vector carrying SERPINA1 (REF. 165 ). Various gene therapy approaches have been designed to increase the levels of circulating α1-antitrypsin, with one having reached phase II testing [165] [166] [167] [168] [169] [170] . Two of these approaches involve haemato poietic stem cell therapy, coupled with delivery of a lentiviral vector containing SERPINA1 (REFS 171, 172) or intrapleural administration of a replication-deficient adeno-associated viral vector containing the SERPINA1 transgene 173 .
Other future potential treatments include the use of iPSCs 144, 174, 175 that are generated from skin fibroblasts harvested from individuals with the PI*ZZ geno type, then reprogrammed to form hepatocyte-like cells that still possess the A1ATD phenotype 144 . Using the CRISPR-CAS9 system to correct the Z mutation in these cells 174 could generate PI*MM cells that share the characteristics of those found in healthy individuals. Theoretically, these cells could be used for autologous grafting without the risk of immune rejection. In vitro reports using this technique are still limited and no clinical trials have been commenced. However, this approach is still promising and might be a long-term answer to the treatment of both lung and liver disease manifestations of A1ATD.
Other disorders α1-Antitrypsin is one member of a large family of serine proteinase inhibitors, known as serpins. Other members of this protease family are mutated in human diseases and so it is likely that data obtained from the study of α1-antitrypsin will have wider biomedical applications. For example, mutant forms of the neuron-specific serpin (neuroserpin) also undergo polymerization and formation of inclusion bodies in the same way as α1-antitrypsin, but the accumulation of mutant neuroserpin leads to neurodegeneration and early-onset dementia 176 . The development of therapeutics that prevent the poly merization of α1-antitrypsin will also rapidly lead to the development of therapies for other serpinopathies that are primarily associ ated with the accumulation of polymers. Similarly, the development of small mol ecules designed to mimic the anti-inflammatory effects of α1-antitrypsin would be applicable for use in other disorders, as α1-antitrypsin augmentation therapy has been shown to be beneficial in other diseases, including cystic fibrosis 177, 178 . Finally, the mechanism by which the accumulation of polymers of α1-antitrypsin in the lumen of the ER can trigger downstream signalling is unknown, but it has been proposed that the ER overload seen in this condition might also mediate cellular responses to enveloped viruses. The study of α1-antitrypsin is highly important and could improve knowledge of other more-prevalent conditions 179, 180 .
